BioNTech (BNTX) Q1 2025 earnings summary

Executive summary

• Advanced oncology pipeline with BNT327 (bispecific anti-PD-L1/anti-VEGF-A) showing promising efficacy and safety in TNBC, ES-SCLC, NSCLC, and mesothelioma, with multiple Phase II/III trials and first combination data expected in 2025.

• mRNA cancer immunotherapies (FixVac, iNeST, BNT116) demonstrated immune response and safety in NSCLC, with ongoing late-stage development.

• Maintained over 50% global COVID-19 vaccine market share, with commercial preparations and regulatory approvals for variant-adapted vaccines in over 40 countries.

• Completed Biotheus acquisition, securing global rights to BNT327 and other assets for ~$800M upfront plus milestones.

• Appointment of Ramón Zapata(-Gomez) as CFO effective July 1, 2025, succeeding Jens Holstein.

Financial highlights

• Q1 2025 revenues were €182.8M–€183M, mainly from COVID-19 vaccine sales, down from €187.6M–€188M in Q1 2024.

• Net loss for Q1 2025 was €415.8M–€416M, compared to €315M–€350M in Q1 2024; loss per share of €1.73 (Q1 2024: €1.31).

• R&D expenses increased to €525.6M–€526M (Q1 2024: €507.5M–€508M), reflecting late-stage clinical development.

• SG&A expenses decreased to €120.6M–€121M (Q1 2024: €132.6M–€133M) due to lower external services.

• Cash, cash equivalents, and security investments totaled €15.9B as of March 31, 2025.

Outlook and guidance

• 2025 revenue guidance: €1.7B–€2.2B; R&D expenses: €2.6B–€2.8B; SG&A: €650M–€750M; capex: €250M–€350M.

• Revenue phasing expected to be back-end loaded, with most sales in the last 3–4 months of the year.

• No positive net income expected for FY 2025; guidance assumes stable vaccination rates and market share.